TO THE EDITOR: Spiegel and colleagues (1) examined the costeffectiveness of cyclooxygenase-2 inhibitors compared with generic naproxen among patients with chronic arthritis. The authors critiqued our health economic analysis comparing rofecoxib with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) and in doing so misstated both our methods and conclusions (2). We would like to address these errors.
GI events was assigned for H 2 antagonists. These approaches and the resulting values were all detailed in the Methods section of our paper.
The utility of health economic analyses for decision making depends greatly on clarity of methods and explicitness in stating the assumptions used in the models. Therefore, it is important for the presentation of analyses based on such models to be both comprehensive and transparent and for the potential implications of any assumptions to be discussed. We feel our previously published model was both transparent in its presentation and comprehensive in its analyses.
In addition, it is important to recognize that many more nonselective NSAIDs, both brand-name and generic, are available and in use for treatment of arthritis in the United States. The article by Spiegel and colleagues compared generic naproxen with rofecoxib and celecoxib (coxibs). However, the conclusions of the paper were not limited to this comparison but instead were generalized to all nonselective NSAIDs. The results of these analyses are quite sensitive to the cost of the nonselective NSAID comparator, and the range of potential nonselective NSAID drug costs extends well beyond the $0.04 to $0.50 range described by Spiegel and colleagues, as used in a probabilistic sensitivity analysis. Comparison of coxibs with a single, generic NSAID without regard to other nonselective NSAID alternatives is useful, but limited.
when endoscopic data are considered (1) . Our statement that Pellissier and colleagues found that rofecoxib was "more effective and cost-saving when compared with nonselective NSAIDs" is precisely in line with their latter conclusion and in fact is the very definition of dominance. We did not specify whether the conclusion arose from their base-case analysis or their sensitivity analysis.
When we compared our analyses, several potential biases were apparent in the work by Pellissier and colleagues. First, although the paper was published in 2001, the authors relied on the 1998 Red Book to adopt their cost estimates. In doing so, they determined that the average wholesale price of a coxib was $2.42 per pill, whereas the current cost is closer to $2.70 (2) . Similarly, using an undisclosed recipe of weighted averages (by market share) of NSAIDs, the authors estimated that nonselective NSAIDs cost $1.47 per pill, compared with average wholesale prices of $0.18 for naproxen and $0.10 for ibuprofen (2) . Moreover, by failing to report sensitivity analyses on either of these key estimates, the authors failed to demonstrate the degree to which they affected the model results. The net effect of these cost assumptions is to improve the relative cost-effectiveness of coxibs versus nonselective NSAIDs.
Second, rather than compare the head-to-head cost-effectiveness of coxibs and nonselective NSAIDs, the authors instead assumed that a proportion in each arm received co-prescribed GI prophylaxis. On the basis of the "input of an expert panel," the authors estimated that the co-prescription of prophylactic agents was "75% less than with nonselective NSAIDs." They further assumed that 25.5% of the nonselective NSAID group received co-prescriptions. Where we reported that all 25.5% received omeprazole, Pellissier and colleagues noted that their analysis allowed for a combination of gastroprotective agents, including misoprostol and H 2 -receptor antagonists. However, the authors did not report the relative proportion of PPI use (that is, did PPIs account for all, half, or none of the 25.5%?). Moreover, because misoprostol is rarely used for GI prophylaxis because of side effects and H 2 -receptor blockers are proven ineffective for this indication, there is little doubt that PPIs are the drug class of choice for NSAID gastropathy. The more important issue is whether co-prescribed therapy should be modeled in the first place. The use of nonselective NSAIDs with co-therapy is a very different strategy from the use of NSAIDs alone and should therefore be the subject of a different analysis. Moreover, co-prescribing therapy is an explicit choice and should emanate from the "decision node" of a decision tree, not a "probability node" as modeled by Pellissier and colleagues. The notion that our hands are tied and that co-prescribing practices are a matter of probability (as determined by an expert panel) serves only to reify current practice rather than to test the real issue: whether coxibs alone are cost-effective versus nonselective NSAIDs alone.
Third, Pellissier and colleagues assumed that PPIs reduce the risk for NSAID-related ulcer complications by 40% versus NSAIDs alone. However, the authors also adopted data from studies indicating that coxibs reduce complications by 50% versus NSAIDs alone. Therefore, the analysis assumes that the combination of an NSAID and a PPI is less effective than a coxib. This is not borne out by recent data indicating that the competing strategies are equally effective (3). Pellissier and colleagues suggested that we failed to test the full range of possible costs for nonselective NSAIDs, since "the range . . . extends well beyond the $0.04 to $0.50 range described." However, Table 5 of our study shows that we extended the range well beyond these constraints. Specifically, we found that the coxib strategy became dominant only when the cost of the NSAID comparator exceeded $2.17, 12 times the average wholesale price of naproxen.
Brennan M.R. Spiegel, MD Ian M. Gralnek, MD, MSHS Veterans Administration Greater Los Angeles Healthcare System Los Angeles, CA 90073
Diagnosis and Management of Adults with Pharyngitis
TO THE EDITOR: I take exception with the conclusions of Neuner and colleagues in their article on the diagnosis and management of adults with pharyngitis (1). I am not an academic, but the late Dr. Louis Weinstein was. He related the following tale on more than one occasion while I was a student at Haynes Memorial Hospital in Boston, Massachusetts, some years ago. Dr. Weinstein became concerned about the validity of throat cultures when he was able to obtain only a 70% positive return on known group A ␤-hemolytic streptococcal infections, using as his gold standard a personally documented increase in the antistreptolysin-O (ASLO) titer (blood was drawn twice, once on seeing the individual for the first time and the second time 2 weeks later). Dr. Weinstein made his own blood agar plates, personally performed the throat culture, and did the serologic work himself. He repeated the study and got identical results. He then spoke with another pioneer in the field, Dr. Charles H. Rammelkamp Jr. in Cincinnati, Ohio, who stated that he, too, obtained the identical result, namely only a 70% positive throat culture return when compared with the ASLO titer increase that proved that any given individual had had the infection in question.
Granted, we are now in another era when immunoassays are in vogue, but the gold standard should still be the ASLO titer, not the throat culture and not the optical (or any other) immunoassay.
Incidentally, I asked Dr. Weinstein what he did clinically. He replied that if he found that he was getting positive throat cultures with any regularity, he would treat all suspicious pharyngeal infections with penicillin or erythromycin.
In any event, in the absence of ASLO titer confirmation, the results quoted in Neuner and colleagues' article remain suspect, at least to me.
Norman D. Corwin, MD
Westwood, NJ 07675 TO THE EDITOR: Neuner and colleagues' cost-effectiveness analysis on the diagnosis and management of adults with pharyngitis (1) concluded that observation, culture, and rapid antigen test strategies for possible group A ␤-hemolytic streptococcal pharyngitis have similar effectiveness. They also concluded that empirical treatment was not the best strategy, regardless of prevalence.
This result assumes that the adverse consequences of antibiotic therapy exceed the derived treatment benefit. The rationale for treating group A ␤-hemolytic streptococcal pharyngitis includes the prevention of suppurative complications (peritonsillar abscess) and nonsuppurative complications (acute rheumatic fever) as well decreasing contagion and relieving symptoms. Neuner and colleagues appropriately considered peritonsillar abscess and acute rheumatic fever but did not address contagion and underestimated the suffering (disutility) of patients with severe pharyngitis. Given that peritonsillar abscess and acute rheumatic fever are rare (2.3% and 0.05%, respectively), accurate utility assessment of pharyngitis becomes paramount. Neuner and colleagues estimated a utility for sore throat of 0.95 by using published patient survey data (2, 3) that compared pharyngitis with other common symptoms, such as diarrhea and dyspepsia. They then used the patient-assigned utility score of 0.95 for diarrhea and dyspepsia (4) as a proxy for pharyngitis. The analysis does not consider that patients who present with severe pharyngitis (at least 3 or 4 clinical findings) would have greater disutility than those with less severe pharyngitis.
To achieve accurate utilities for adult pharyngitis, Rousculp (5) recently administered a utility survey using a modified time-tradeoff method. In his survey, the mean utility for mild pharyngitis was 0.945; however, the utility score dropped to 0.861 for severe pharyngitis. If Neuner and colleagues had applied pharyngitis utilities that took symptom severity into account, we suspect that in patients with severe sore throat, empirical therapy may have been the most effective and least expensive, that is, dominant. riety of other tests have varied in the literature, as we reviewed in our article and its appendix. Probably because ASLO assessment takes at least a week and thus cannot be used for treatment decisions in the clinical setting, there is unfortunately little information regarding ASLO titers in a group of patients "suspicious" for streptococcal pharyngitis or in patients receiving rapid immunoassay testing. This lack of data made it difficult for us to use ASLO as our gold standard. Furthermore, some of the issues regarding sensitivity may be reduced with careful attention to culture technique (1) , and recent studies using polymerase chain reaction to assess both immunoassays and pharyngeal culture suggest that test performance of culture is much better than the 70% sensitivity cited by Dr. Corwin (2) . For these reasons, although we agree that it is less than ideal, we and authors of similar studies have chosen to use pharyngeal culture as a gold standard.
Drs. Cohen and Centor report some interesting unpublished data (3) on the patient utility for sore throat and are concerned that our analysis of patients with severe pharyngitis (that is, those who had positive results on 3 to 4 Centor criteria) did not take into account the possibility of a different utility for these patients. Although our estimates for the sequelae of sore throat were taken from a patient survey that compared them with sore throat (4), our utility estimate for pharyngitis was certainly limited by the lack of information in the literature on patients' utilities for sore throat. We note that our utility estimate for our base-case scenario was identical to that reported by Drs. Cohen and Centor for "mild" pharyngitis. We agree with Drs. Centor and Cohen that patient disutilities vary for many disease states and are likely to be higher on average in patients with more severe symptoms and signs of pharyngitis. In pharyngitis, a disease in which sequelae are rare, individual patient disutilities should be carefully considered and may indeed drive decision making. The typical patient encountered in primary care has a less severe sore throat, so the incorporation of Rousculp's findings would not change our main, baseline findings. Empirical therapy without testing was neither the most effective nor least expensive strategy at any prevalence of group A ␤-hemolytic streptococcal infection typically seen in adult populations. 
Joan Neuner, MD

Mammography and Palpable Breast Abnormalities
TO THE EDITOR: In their article on evaluation of abnormal mammography results and palpable breast abnormalities, Kerlikowske and colleagues (1) calculated likelihood ratios correctly but incorrectly defined the term in their footnotes to Tables 2, 3, and 5. They defined a likelihood ratio as "the ratio of diseased to nondiseased persons for a given test result." A hypothetical example illustrates why this is incorrect. If among patients with a positive test result 90 had a given disease and 1 did not, and if among patients with a negative test result 10 had the disease and 9 did not, the ratio of diseased to nondiseased persons for a positive test result would be 90 to 1. However, the likelihood ratio for a positive test result would be 90%/10%, or 9. Very different.
One of several correct definitions of a likelihood ratio is "the ratio of the relative frequency of a given test result in diseased and nondiseased persons (where relative frequency is a proportion)" (2) .
Errors in defining likelihood ratios are common. An early edition of a classic text on clinical epidemiology contains errors (3), describing a likelihood ratio as an odds or a ratio of odds (rather than a ratio of probabilities). The current edition of a popular text on diagnostic tests contains a similar error (4). Some texts commit more serious errors-incorrectly calculating likelihood ratios in addition to incorrectly defining them (5, 6)-actually applying the erroneous definition used by Kerlikowske and colleagues.
Arthur T. Evans, MD, MPH Cook County Hospital and Rush Medical College Chicago, IL 60612
IN RESPONSE: We appreciate Dr. Evans's correspondence and the opportunity to clarify the use of the term likelihood ratios in our paper. Likelihood ratios are being used more frequently by clinicians in clinical practice but are still not as familiar as the sensitivity and specificity of a diagnostic test. Sensitivity is calculated among diseased persons and specificity is calculated among nondiseased persons, whereas likelihood ratios are calculated using a given test result among diseased and nondiseased persons, as noted in the footnotes of our Tables 2, 3, and 5. As stated by Dr. Evans, the likelihood ratios reported in our article are calculated correctly for screening and diagnostic mammography and fine-needle aspiration biopsy, and a clear description of how to apply likelihood ratios for these tests in clinical practice is provided. We reference the source data (1) used to calculate likelihood ratios reported in our paper as well as the formulas, which are as follows.
Positive likelihood ratio ϭ sensitivity/1 Ϫ specificity Negative likelihood ratio ϭ 1 Ϫ sensitivity/specificity These formulas show that likelihood ratios are calculated as the probability that persons with the disease have a particular test result divided by the probability that persons without the disease have the same test result. Additional information on how to calculate likelihood ratios for a given test result can be found in a classic epidemiology text (2) .
Karla Kerlikowske, MD San Francisco Veterans Affairs Medical Center San Francisco, CA 94121
The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy
TO THE EDITOR:
In their article on the discrepancy between observational studies and randomized trials of menopausal hormone therapy, Col and Pauker (1) correctly recognized that differences in socioeconomic status or other risk factors ("healthy user effect") between postmenopausal hormone users and nonusers are unlikely to substantially explain differences in the coronary heart disease (CHD) findings from the Nurses' Health Study (NHS) (2) and the Women's Health Initiative (WHI) trial (3). They noted, as we have (4), that any such effects would also alter findings for other diseases, especially stroke. The nearly identical results from the NHS and WHI for stroke suggest that the explanation for the difference in CHD lies elsewhere. Col and Pauker speculated that misclassification of CHD in the NHS and other observational studies biased the findings. They suggested that if women taking hormones thought they were protected from heart attack, they would be less likely to present with its symptoms. However, one could as easily speculate that the health-conscious women taking hormones would be more likely to seek medical attention for symptoms than nonusers. Also, in the NHS, we do not include silent infarctions (because we cannot perform periodic electrocardiography in this large cohort). Col and Pauker speculated that this omission biased the findings, claiming that one third of infarcts are silent. This ignores the WHI finding that 3% (9 of 265) of nonfatal myocardial infarctions were silent (3) and that results were identical whether silent infarctions were included or excluded. Even extreme bias in this small group would have negligible impact.
Col and Pauker also suggested systematic misclassification of CHD death in the NHS. They implied that investigators' coding of cause of death could alter the diagnosis on the basis of medication use. We apply uniform and strict criteria for CHD, similar to the WHI. Fatal CHD is based on previous evidence of CHD, diagnostic tests, clinical findings, autopsy reports, and the death certificate. Previous medication use is not reviewed and is included in less than Letters 20% of CHD death files. Most fatal CHD codes are based on previously diagnosed CHD and the death certificate. Moreover, the NHS results for nonfatal MI and fatal CHD were nearly identical, and authors accept our adjudication process for nonfatal MI. Finally, widespread belief that hormones were protective for CHD developed only over the past 15 to 20 years. Thus, if expectations of physicians or investigators led to an association because of misclassification of CHD, one would expect an increasing apparent benefit of hormones over time. In fact, the NHS observation of a lower risk among hormone users was present in data from 1976 to 1980 (5) , and the magnitude of the association has not increased since then.
A more plausible explanation of differences between NHS and WHI is based on biology and differences in the populations. In the NHS, and most observational studies, most hormone use began at menopause. In contrast, 67% of WHI participants were 60 years of age or older. The WHI found a trend toward lower risk with decreasing time since menopause; among women who went through menopause less than 10 years previously (n ϭ 65), the relative risk for CHD with estrogen plus progestin compared with placebo was 0.89 (95% CI, 0.55 to 1.46). For women for whom 10 to 19 years had passed since menopause, the relative risk was 1.22, and for those who had menopause 20 or more years previously, it was 1.71 (3) . Such findings are consistent with studies showing that estrogen benefits were reversed in the presence of endothelial dysfunction in rabbits (6) . Likewise, monkeys that began receiving hormone therapy at ovariectomy had reduced atherosclerosis, but those who started therapy years after ovariectomy had no benefit (7) . In women, atherosclerosis abrogates the estrogen effect on vasodilatation (8) . In a randomized trial among younger postmenopausal women, estrogen significantly reduced carotid atherosclerosis progression compared with placebo (9) . Thus, a likely explanation for the different results from WHI and NHS is the difference in age at starting hormone use.
IN RESPONSE:
Despite mounting evidence concerning the risks of hormone therapy, the NHS authors still believe that it is cardioprotective if initiated in newly menopausal women without atherosclerosis. However, NHS data show that the cardioprotective effect was the same among women in their 50s and 60s (relative risk, 0.71 vs. 0.66) and among women with and without CHD risk factors (1). Grodstein and colleagues' argument hinges on one statistically insignificant subgroup analysis of WHI women within 10 years of menopause (relative risk, 0.89; 65 CHD cases). Of note, subgroup analysis of WHI women 50 to 59 years of age yielded conflicting results: a relative risk of 1.27. Because of the complexities of dating menopause, the subgroup defined by age is probably the more robust estimate of the effect of hormone therapy among newly menopausal women.
The NHS authors have not recognized the importance of unblinded assessment of outcomes. The bias introduced by the lack of concealment of treatment allocation is substantial and has been empirically demonstrated among randomized, controlled trials. Unblinded trials substantially overestimate (41%) treatment effects compared with blinded trials (2) . The impact of unblinding within observational studies could potentially be larger given the other potential sources of bias within nonrandomized studies.
The NHS authors dispute the potential impact of excluding silent events, stating that the rate of silent events in their study should mirror the 3% reported in the WHI rather than the 34% range reported in the Framingham Study and many other population-based studies (3) . Because risk factors for silent myocardial infarction were similar in the NHS and the Framingham Study, their rates should also be similar. In contrast, silent event rates in population-based studies should not mirror those in randomized, controlled trials, whose protocols were designed to recognize adverse events that might otherwise have gone unnoticed.
Literature on the purported cardioprotective effect of hormones long predates the NHS observation period. In the 1960s, 2 trials were published (4, 5) and a third nationwide collaborative study began, all hoping to extend cardioprotection from women to men (6) . In 1985, one explanation offered for discrepant results between the first NHS and the Framingham Study was predicated on the widespread belief that hormone therapy was cardioprotective: "Could the [Framingham Study] data . . . be seriously biased by one or several physicians who were unusually alert to possible estrogen effects?" (7) .
Is it plausible to believe that hormone therapy prevents CHD in newly menopausal women but induces it in all others? While this issue is not completely resolvable with the data at hand, the argument for such a window rests on one statistically insignificant, discordant subgroup analysis from the WHI and 3 small studies of unopposed estrogen. Unopposed estrogen is markedly different from combined estrogen and progesterone in its effects on the heart. One of these studies (8) , involving only 83 women, found an inconsequential 0.0053-mm change in arterial walls; the other studies were in animals (9, 10) . Should the treatment of all women be driven by these data despite the experience of 16 608 women in a well-designed randomized, controlled trial? We believe not and think that clinicians should continue to advise only substantially symptomatic women to take hormone therapy. Stephen G. Pauker, MD Tufts-New England Medical Center Boston, MA 02111 were used as controls. This study was conducted in compliance with local institutional review board regulations and the revised Helsinki protocol.
Both the 13 C-urea breath test and anti-CagA antibodies became negative in 8 of 11 patients with H. pylori infection who completed the eradicating therapy but remained positive in the 3 patients who did not complete the treatment. Before therapy, 5 of these 11 patients had anti-glycoprotein (GP) IIb/IIIa antibodies; no changes in antibody levels were observed in the 3 patients who were positive for anti-GP IIb/IIIa antibodies but had successful eradication therapy or in the 2 patients in whom therapy failed. Mean platelet counts (ϮSD) increased significantly only in patients with successful H. pylori eradication (86 Ϯ 25 vs. 168 Ϯ 68 ϫ 10 9 cells/L; P Ͻ 0.001). No significant changes were observed in unsuccessfully treated patients (88 Ϯ 23 vs. 100 Ϯ 28 ϫ 10 9 cells/L; P Ͼ 0.2) or in untreated H. pylori-negative patients with ITP (103 Ϯ 27 vs. 84 Ϯ 25 ϫ 10 9 cells; P Ͼ 0.05). Mean platelet counts (ϮSD) increased in 3 anti-GP IIb/IIIa-positive patients (from 83 Ϯ 24 to 118 Ϯ 48 ϫ 10 9 cells/L; P Ͻ 0.04) and in 5 anti-GP IIb/IIIanegative patients (from 89 Ϯ 26 to 218 Ϯ 88 ϫ 10 9 cells/L; P Ͻ 0.001).
Anti-CagA antibodies reacted with all platelet samples. However, a single 50-kDa band was detected in 5 of 6 samples from normal controls, and 2 bands (50 kDa and 55 kDa) were detected in all samples from patients with active ITP and resolved ITP (Figure  2) . The immunoreaction of anti-CagA antibodies with the 55-kDa platelet antigen was significantly associated with resolved or active ITP (P Ͻ 0.01). In neither smooth-muscle nor normal artery lysates did anti-CagA antibodies react with the 50-kDa or the 55-kDa bands.
Conclusions: Our hematologic and serologic data support a temporal association between the disappearance of anti-CagA antibodies in the serum and improvement of ITP. Moreover, anti-CagA antibodies recognized 2 platelet antigens in ITP patients but only 1 in normal controls. We hypothesize that anti-CagA antibodies could lead to reduced platelet survival only in patients displaying the 55-kDa platelet antigen. Additional studies are necessary to identify the cross-reacting platelet antigens and their population prevalence.
